Business Wire

Ripple Announces $500 Million Strategic Investment Led by Fortress and Citadel Securities, Valuing the Company at $40 Billion Following Record Growth

5.11.2025 15:00:00 CET | Business Wire | Press Release

Share

Ripple, the leading financial technology company that offers crypto solutions for businesses, today announced a $500 million strategic investment at a $40 billion valuation from world-class institutional investors led by funds managed by affiliates of Fortress Investment Group, affiliates of Citadel Securities, Pantera Capital, Galaxy Digital, Brevan Howard, and Marshall Wace. The investment follows Ripple’s strongest year to date and its recent $1 billion tender offer at the same valuation, underscoring continued confidence in the company’s growth trajectory and long-term vision.

As Ripple continues its record year of growth, providing liquidity for shareholders and employees remains a priority. The company has repurchased more than 25% of its outstanding shares in recent years, returning meaningful value to employees and early investors. Its most recent tender offer attracted significant interest from institutional investors eager to join Ripple’s cap table. The decision to accept $500 million in new common equity reflects the strategic value of deepening relationships with financial partners whose expertise complements Ripple’s expanding global suite of products.

“This investment reflects both Ripple’s incredible momentum, and further validation of the market opportunity we’re aggressively pursuing by some of the most trusted financial institutions in the world,” said Brad Garlinghouse, Ripple CEO. “We started in 2012 with one use case - payments - and have expanded that success into custody, stablecoins, prime brokerage and corporate treasury, leveraging digital assets like XRP. Today, Ripple stands as the partner for institutions looking to access crypto and blockchain.”

In just over two years, Ripple completed six acquisitions, including two valued at over $1 billion, expanding its footprint across payments, custody, and stablecoins, while entering new markets in prime brokerage and treasury management.

Payments have quickly become one of the most practical and scalable applications of crypto. Earlier this year, the company acquired stablecoin infrastructure company Rail, adding capabilities to Ripple Payments as a full-service cross-border platform, using Ripple USD (RLUSD) and XRP, to make global money movement faster and more efficient for businesses. With 75 regulatory licenses, Ripple can move money on behalf of its customers, cutting out intermediaries, and simplifying liquidity management and on-and-off ramps. Total Ripple Payments volumes have now surpassed $95 billion, a clear sign of growing demand and real-world utility.

In a post-GENIUS Act world, institutions are increasingly turning to trusted stablecoins like RLUSD for use cases such as treasury payments and collateral – a key reason why Ripple acquired GTreasury in October. GTreasury manages trillions of dollars of volume for its Fortune 500 customers who are keen to use stablecoins and digital assets to move money 24/7/365, and put their idle capital to work.

Just this week, RLUSD crossed a $1 billion market cap in less than a year since launch. Ripple also recently completed its acquisition of Hidden Road, now known as Ripple Prime, where RLUSD is already in use as collateral. Since the deal was announced, client collateral has doubled, average daily transactions have climbed to more than 60 million, and the business has tripled in size. Ripple Prime is now expanding into collateralized lending for XRP and supporting a rapidly growing base of institutions trading XRP-based products.

About Ripple

Ripple is a financial technology company that offers crypto solutions for businesses. Ripple Payments uses blockchain to make cross-border payments faster, more transparent, and widely accessible. Ripple Custody offers customers a secure way to store and manage digital assets. Through Ripple Prime, the company offers a global, multi-asset prime brokerage for institutional customers. Ripple's stablecoin (RLUSD) and the cryptocurrency, XRP, are leveraged across these solutions to make traditional finance more efficient and enable new ways to utilize digital assets.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105757111/en/

Contacts

Media Contact
Stacey Ngo
Press@ripple.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye